Clinical Trials Logo

Recurrence clinical trials

View clinical trials related to Recurrence.

Filter by:

NCT ID: NCT06390228 Completed - Recurrence Clinical Trials

Impact of Hepatectomy on HCC Recurrence

HCC
Start date: January 1, 2019
Phase:
Study type: Observational

Hepatectomy is the first option for the treatment of hepatocellular carcinoma(HCC) at CNLC Ib stage. HCC patients who undergo curative hepatectomy may experience varying remnant liver volumes and thus leads to different oncological outcomes.

NCT ID: NCT06389591 Not yet recruiting - Clinical trials for Recurrent Glioblastoma

RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)

Start date: December 2024
Phase: Phase 1
Study type: Interventional

This is a Phase I study to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in adult patients with recurrent glioblastoma.

NCT ID: NCT06386315 Not yet recruiting - Clinical trials for Indolent B-Cell Non-Hodgkin Lymphoma

Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma

Start date: May 1, 2024
Phase: Phase 2
Study type: Interventional

This phase II trial compares the safety, side effects and effectiveness of reduced dose radiation therapy to standard of care dose radiation in treating patients with indolent non-Hodgkin lymphoma. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Standard of care radiation treatment for indolent non-Hodgkin lymphoma is usually delivered in 12 treatments. Studies have shown indolent lymphoma to be sensitive to radiation treatment, however, larger doses have higher rates of toxicities. A reduced radiation dose may be safe, tolerable and/or effective compared to standard of care radiation dose in treating patients with indolent non-Hodgkin lymphoma.

NCT ID: NCT06385327 Not yet recruiting - Clinical trials for Recurrent Genital Herpes Simplex Type 2

A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-5366 in Healthy Participants and Participants Seropositive for HSV-2 With Recurrent Genital Herpes

Start date: May 2024
Phase: Phase 1
Study type: Interventional

This study is designed to assess safety, tolerability, and pharmacokinetics (PK) of single ascending dose (SAD) of ABI-5366 in Part A in healthy participants and multiple-ascending doses (MAD) of ABI-5366 in Part B in participants seropositive for Herpes Simplex Virus Type 2 (HSV-2) with recurrent genital herpes. Effect of food will also be evaluated in Part A.

NCT ID: NCT06385080 Recruiting - Clinical trials for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/Metastatic Head and Neck Cancer

OrigAMI-4
Start date: April 22, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, and amivantamab in addition to paclitaxel in participants with recurrent/metastatic head and neck cancer. The study will also confirm the recommended Phase 2 combination dose (RP2CD) for amivantamab in addition to paclitaxel.

NCT ID: NCT06384482 Recruiting - Clinical trials for Recurrent/Refractory Small Cell Lung Cancer Lung Large Cell Neuroendocrine Carcinoma

SNC115 Injections in Patients With Recurrent/Refractory Small Cell Lung Cancer and Lung Large Cell Neuroendocrine Carcinoma

Start date: April 30, 2024
Phase: Phase 1
Study type: Interventional

This study is a FIH dose escalation clinical study, with single arm, open label and design, in order to observe the preliminary safety and Pharmacokinetic of SNC115 Injection in participants with Recurrent/refractory small cell lung cancer and Lung large cell neuroendocrine carcinoma.

NCT ID: NCT06382818 Not yet recruiting - Breast Cancer Clinical Trials

Personalization of Breast Radiotherapy According to Loco-regional Recurrence Risk and Toxicity Probability

PROBA
Start date: April 26, 2024
Phase: N/A
Study type: Interventional

Our objective is based on a personalized approach of adjuvant breast radiotherapy by selecting patients according to tumor recurrence and toxicity risk.

NCT ID: NCT06382415 Completed - Rectal Cancer Clinical Trials

Organ/Space Surgical Site Infection and Recurrence and Survival in Rectal Cancer Surgery

VINCat_PDO_2
Start date: January 1, 2011
Phase:
Study type: Observational

In rectal cancer surgery, the organ/space surgical site infection (O/S-SSI) has an impact on patient's prognosis. Its influence in the oncologic outcomes remains controversial. The main objective is to assess the possible effect of O/S-SSI on long-term overall survival and cancer recurrence.

NCT ID: NCT06380036 Completed - Fistula in Ano Clinical Trials

Two Approaches to Lower the Chances of Recurrence of Anal Fistula After Surgery

Start date: November 1, 2022
Phase: N/A
Study type: Interventional

A total of 80 patients with complex fistula in ano of both genders were included. All patients in Group A underwent a loose seton technique. In group B, video-assisted fistula tract surgery (VAAFTS) was performed.Twice daily Sitz baths, analgesics, and stool bulking agents (bran) were used in follow-up care. Repeated examinations were carried out every four weeks and recurrence was noted at the end of three months

NCT ID: NCT06379321 Not yet recruiting - Recurrence Clinical Trials

A Retrospective/Prospective, Post-market Evaluation of Outcomes of the Triathlon Hinge Knee (THK) System

Hinge
Start date: May 1, 2024
Phase:
Study type: Observational

This study is a prospectively and retrospectively enrolled, post-market, open-label, non-randomized, single institution evaluation of clinical outcomes of primary or revision knee surgery patients who meet the eligibility criteria and received devices from the Triathlon Hinge Knee System according to its indications for use (IFU). Clinical evaluation for all cases will include data collection of patient demographics, surgical details, early postoperative status, functional and clinical outcomes, and survivorship at 1, 2, 6, and 10-years.